Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002953 | 0.88 | CCR8 (0.56) | SIGMAR1L3MBTL1POLBSYK | |
| SCHEMBL13826659 | 0.88 | SIGMAR1 (0.60) | SIGMAR1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL16002916 | 0.87 | SMN1; SMN2 (0.56) | SIGMAR1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL16003083 | 0.84 | SIGMAR1 (0.53) | SIGMAR1KMT2AMEN1L3MBTL1POLB | |
| SCHEMBL16003002 | 0.82 | SIGMAR1 (0.55) | SIGMAR1KMT2AMEN1L3MBTL1POLB | |
| SCHEMBL13182998 | 0.82 | ALDH1A1 (0.66) | SIGMAR1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL16002918 | 0.80 | HDAC3 (0.55) | SIGMAR1KMT2AMEN1L3MBTL1SYK | |
| SCHEMBL16002967 | 0.80 | MLNR (0.54) | L3MBTL1POLBSYK | |
| SCHEMBL16002963 | 0.80 | MEN1 (0.69) | SIGMAR1KMT2AMEN1POLBOPRK1 | |
| SCHEMBL16002988 | 0.79 | EPHX2 (0.56) | KMT2AMEN1MAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SIGMAR1 2509/4885KMT2A 2649/4885MEN1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.